<DOC>
	<DOCNO>NCT02912325</DOCNO>
	<brief_summary>The primary objective evaluate efficacy FaseMETS 6 consecutive month lower serum lipid glucose subject Metabolic Syndrome ; The secondary objective trial : - evaluate potential benefit 3 month therapy ( interim analysis ) - evaluate safety FaseMETS</brief_summary>
	<brief_title>Non-Comparative Study Assess Efficacy Safety New Food Supplement FaseMETS</brief_title>
	<detailed_description>The trial design multicenter , open label , non-comparative , 6 month , pilot study . The primary objective evaluate efficacy FaseMetS ® administer 6 month treatment combine health management plan reduce serum lipidemic profile ( include total cholesterol , LDL cholesterol , HDL cholesterol , small density LDL particle , triglyceride , serum glucose , glycated haemoglobin ( HBA1c ) , insulin , pro-insulin , HOMA index , uric acid , body mass index ( BMI ) , creatine phosphokinase ) patient diagnose Metabolic Syndrome mild moderate Hypercholesterolemia . The secondary objective : - evaluate efficacy reduce serum lipidemic profile period 3 month FaseMetS ® ® treatment ; - evaluate safety FaseMetS ® treatment record AE/SAE ( particular regard gastrointestinal symptom ) ; - improvement blood clinical laboratory parameter ; - improvement weight control systolic blood pressure diastolic blood pressure control</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>men woman age &gt; 45 ≤70 year cardiovascular disease prevention clinical practice write informed consent . total cholesterol≥240 mg/dL diagnosis metabolic syndrome three follow : Waist circumference : ≥89 cm woman ≥102 cm men BMI≥30 Kg/m2 ; Triglycerides level : ≥ 175 mg/dL 1.7 mmol/L HDL &lt; 40 mg/dL ( 1.04 mmol/L ) men &lt; 50 mg/dL ( 1.3 mmol/L ) woman Blood sugar ( fast plasma glucose ) : ≥120 mg/dL ( 6.7 mmol/L ) Pregnancy lactation ; Patients high low cardiovascular risk , calculate SCORE ≥10 % &lt; 1 % respectively History atrial fibrillation atrial flutter Patient treatment indication oral anticoagulant antithrombotic drug Patients severe gastrointestinal tract disorder possible influence drug absorption electrolyte . Patients myeloproliferative disorder Patients severe chronic kidney disease ( GFR 30 mL/min/ 1.73 m2 ) , use Cockcroft 's formula , know liver disease biliary obstructive disorder , chronic hepatitis , cirrhosis , hyperkalemia ALAT ASAT upper 3 time upper limit normal laboratory range . History alcoholism drug abuse . Uncontrolled dysthyroidism , Cushing 's syndrome , acromegalia , hyperparathyroidism . Patients HIV take drug HIV . Patients take statin dyslipidemic /hypolipidemic agent ( drug , food supplement , etc ) . Patients take antidiabetic drug ( i.e metformin , acarbose and/or others ) . Patients unlikely cooperate study comply well treatment study visit . Participation another study time within precede 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>